Here we present PRO data from STARTRK-2, which provide additional evidence to support the association of entrectinib with clinically meaningful benefit in patients with NTRK fusion-positive solid tumours or ROS1 fusion-positive NSCLC.8 Here, ROS1 is linked to non-small cell lung carcinoma.